Japan’s Eisai Says It Still Has Patent Protection For Aricept Despite Court Action (Japan)
This article was originally published in PharmAsia News
Japan's Eisai says a U.S. district court ruling will have no impact on the validity of its patent for Aricept (donepezil hydrochloride) for treating Alzheimer's disease. The court in New Jersey threw out Eisai's suit against Mutual Pharmaceutical for seeking U.S. FDA approval for an Aricept generic. Eisai said the ruling was based on procedural grounds and it is still free to sue Mutual to defend a patent not set to expire until 2010. (Click here for more - may require a subscription
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.